ArticleScientific reports2025
Comparative analysis of clinical features, methylation and immune microenvironment in pediatric and adult papillary craniopharyngiomas: results from a multicenter study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?Journal of neuro-oncology · 2026Pooled it
- Systemic Molecularly Targeted Therapies for Neoadjuvant and Salvage Craniopharyngioma: A Contemporary Narrative Review.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Papillary craniopharyngioma (PCP) was previously believed to occur only in adults. Sporadic pediatric PCP (PPCP), confirmed by detection of the BRAF V600E mutation, has been reported since 2018. The differences between PPCP and adult PCP (APCP) remain unclear. This comprehensive study aimed to enhance understanding of PPCP and elucidate the distinctions between PPCP and APCP. We conducted a systematic analysis of cases of PPCP and APCP, focusing on BRAF V600E mutation, methylation profiles, histology, cell proliferation, imaging features, immune microenvironment, and prognosis. This study compiled 17 cases of PPCP from 6 medical centers, constituting 3.11% of the total 546 PCP cases. Both PPCP and APCP cases exhibited the BRAF V600E mutation with no differences in methylation patterns. However, imaging showed PPCP was predominantly cystic and located beneath the diaphragma sellae with some progression to the sella. APCP typically manifested as solid lesions, primarily located in the suprasellar region, inferior to the third ventricle. PPCP histologically displayed extensive inflammatory cellular infiltration, suppurative change, and occasional small granular calcifications, whereas APCP was largely devoid of calcifications. Compared to APCP, PPCP exhibited significantly lower PD-L1 (an immune checkpoint protein expressed on tumor cells) expression and higher expression levels of CD38 (an immunosuppressive marker), S100A8/A9 (a neutrophil marker), and MPO (myeloperoxidase, a neutrophil marker). Additionally, stromal expression of CD163 (an M2 macrophage marker) was lower in PPCP compared to APCP, while CD68 (an M1 macrophage marker), CD3 (T cell marker), and CD20 (B cell marker) expression showed no significant difference. Ki-67 expression exhibited a banded pattern on PPCP epithelium, contrasting with a punctate pattern in APCP, with significantly higher levels observed in PPCP. Postoperative prognosis did not differ between PPCP and APCP. While driver genes and methylation profiles may not differentiate PPCP from APCP, substantial discrepancies exist in tumor location, histology, imaging features, cell proliferation, and immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.